Letter: vedolizumab or a second anti-TNF—no difference in efficacy for primary biologic failures with IBD

Maria Giulia Demarzo, Giorgia Bodini, Mattia Vanello, Martina Martini, Edoardo G. Giannini

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)1044-1045
Number of pages2
JournalAlimentary Pharmacology and Therapeutics
Issue number9
Publication statusPublished - May 2021

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology
  • Pharmacology (medical)

Cite this